New drug cocktail shows promise in shrinking lung tumors before surgery

NCT ID NCT07538193

Not yet recruiting Disease control Sponsor: Tang-Du Hospital Source: ClinicalTrials.gov ↗

First seen Apr 22, 2026 · Last updated Jun 19, 2026 · Updated 10 times

Summary

This study tests a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy given before surgery for people with a specific type of advanced lung cancer (stage III-N2b non-small cell lung cancer). The goal is to see if this treatment can shrink or eliminate tumors before surgical removal. About 28 participants will receive three cycles of the drug combo, then undergo surgery. The main measure of success is how many patients have no cancer cells left in their removed tissue.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG (NSCLC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Tangdu Hospitial

Xi'an, Shannxi, China

Conditions

The condition(s) this trial relates to.

carcinoma Lymphatic Metastasis metastatic malignant neoplasm in the lymph nodes non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG (NSCLC) LYMPHATIC METASTASIS LYMPHATIC METASTASIS NEOPLASM STAGING